Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Shares Outstanding (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Shares Outstanding for 14 consecutive years, with $106.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 0.81% to $106.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.0 million through Dec 2025, up 0.81% year-over-year, with the annual reading at $106.0 million for FY2025, 0.81% up from the prior year.
  • Shares Outstanding hit $142.5 million in Q4 2025 for Corcept Therapeutics, up from $105.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $142.5 million in Q4 2025 to a low of $102.5 million in Q2 2023.
  • Historically, Shares Outstanding has averaged $108.8 million across 5 years, with a median of $106.0 million in 2021.
  • Biggest five-year swings in Shares Outstanding: fell 9.25% in 2021 and later increased 1.88% in 2025.
  • Year by year, Shares Outstanding stood at $105.9 million in 2021, then increased by 1.79% to $107.8 million in 2022, then fell by 4.11% to $103.4 million in 2023, then rose by 1.65% to $105.1 million in 2024, then grew by 0.81% to $106.0 million in 2025.
  • Business Quant data shows Shares Outstanding for CORT at $106.0 million in Q4 2025, $105.1 million in Q3 2025, and $105.3 million in Q2 2025.